Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated a positive financial trajectory, reporting 4Q25 revenues of $174.4 million, marking a 4% increase quarter-over-quarter and an 8% increase year-over-year for full-year 2025, with total revenue reaching $655.4 million. The growth is attributed to strong domestic sales of Optune Gio in the treatment of glioblastoma and significant contributions from international markets, highlighted by national reimbursement in Spain expected to drive future revenue gains. Additionally, ongoing clinical trials and a strategic sales force approach are anticipated to bolster the company's growth prospects in key cancer treatment areas, including non-small cell lung cancer and pancreatic cancer.

Bears say

NovoCure Ltd is experiencing a downward adjustment in revenue estimates for 2026, with projections for Glioblastoma (GBM) revenue reduced from $702 million to $690 million, while overall total revenue expectations have decreased from $738.9 million to $711.3 million. The company faces significant risks, including potential safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory concerns, and issues related to intellectual property protection. Additionally, challenges in the commercial rollout of its Non-small cell lung cancer (NSCLC) treatment have led to further downgrades in revenue estimates for both the U.S. and European markets, exemplifying the underlying vulnerabilities in NovoCure's financial outlook.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Apr 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.